Literature DB >> 9873224

Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice.

A Afek1, J George, Y Shoenfeld, B Gilburd, Y Levy, A Shaish, P Keren, Z Janackovic, I Goldberg, J Kopolovic, D Harats.   

Abstract

We have previously shown that low density lipoprotein receptor-deficient (LDL-RD) mice immunized with beta2-glycoprotein I (beta2GPI; a target of autoimmune anticardiolipin antibodies) developed enhanced early atherosclerosis, when fed a normal chow diet. The current study was undertaken to evaluate the effect of immunization with beta2GPI and the addition of a high fat diet on the progression of atherosclerosis in the apolipoprotein E (ApoE)-deficient mouse. Six-week-old female ApoE-deficient mice (n = 10) were immunized subcutaneously with either human beta2GPI or with ovalbumin, both emulsified in complete Freund's adjuvant and fed a high fat diet for 6 weeks. The beta2GPI-immunized mice were found to develop accelerated atherosclerosis when compared with their ovalbumin-immunized littermates (aortic lesion area of 137,500 +/- 13,801 vs. 72,444 +/- 14,465 microm2, respectively; p = 0.0067). The beta2GPI-immunized mice developed high titers of anti-beta2GPI antibodies, 10 days after the procedure, which were sustained until the sacrifice. LDL extracted from both study groups displayed similar susceptibility to ex vivo oxidation. These results confirm our previous study in which we found increased atherosclerosis in beta2GPI-immunized LDL-RD mice fed a chow diet. In the current study we show that the proatherogenic effect of beta2GPI immunization is maintained despite high cholesterol levels and is not associated with increased susceptibility of LDL to ex vivo oxidation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873224     DOI: 10.1159/000028046

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  12 in total

Review 1.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Immunomodulation of vascular diseases: atherosclerosis and autoimmunity.

Authors:  G-P Shi
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-02-25       Impact factor: 7.069

Review 3.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

4.  Atherosclerosis.

Authors:  Y Sherer; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 5.  Natural killer T cells and atherosclerosis: form and function meet pathogenesis.

Authors:  Nicole A Braun; Roman Covarrubias; Amy S Major
Journal:  J Innate Immun       Date:  2010-03-17       Impact factor: 7.349

Review 6.  Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis.

Authors:  Y Sherer; Y Shoenfeld
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

7.  Antiphospholipid antibodies from a patient with primary antiphospholipid syndrome enhance experimental atherosclerosis.

Authors:  Arnon Adler; Arnon Afek; Yair Levy; Gad Keren; Jacob George
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-01-13

Review 8.  Autoimmunity in atherosclerosis. The role of autoantigens.

Authors:  J George; D Harats; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

Review 9.  Cardiovascular risk factors in the antiphospholipid syndrome.

Authors:  Felipe Freire da Silva; Roger Abramino Levy; Jozélio Freire de Carvalho
Journal:  J Immunol Res       Date:  2014-07-13       Impact factor: 4.818

Review 10.  β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease.

Authors:  Joyce Rauch; David Salem; Rebecca Subang; Masataka Kuwana; Jerrold S Levine
Journal:  Front Immunol       Date:  2018-12-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.